An observational study in Thrombosis, Bleeding and Coronary Artery Disease (CAD), sponsored by Xueyan Zhao. Recruiting at 3 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by Xueyan Zhao · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies in Thrombosis with a site in China — 18 open to participants now, 20 under way, none of them phase 3. Thrombosis · China.
Among the 67 studies in Thrombosis with a site in China, this one has the largest planned enrollment of the 26 observational ones that give a count, is one of 4 that started in 2025, is one of 26 observational ones, reaches primary completion later than 16 of the 19 other live ones, and was the 61st registered.
956 studies on the registry are indexed under Thrombosis; 172 are open to participants now.
Browse Thrombosis studies →18 of the 67 studies in Thrombosis with a site in China are open now. Recruiting first, the newest first:
Tianjin Medical University · Sites in China
Ages 18–90 · Healthy volunteers
Sun Yat-sen University · Sites in China
Ages 18–75
Peking University People's Hospital · Sites in China
Healthy volunteers
China National Center for Cardiovascular Diseases · Sites in China
Ages 18–65
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 128 Thrombosis studies recruiting now, 80 (63%) set no upper age limit and 17 (13%) stop at 75 or younger; 21 take children under 18; 21 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 3 · Phase 3 7 · Phase 4 8
First in 2002; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 12,154 is above the median of 173 across 384 observational studies indexed under Thrombosis.
Median enrollment 274 across the 41 interventional studies, 500 across the 26 observational. Of the 37 that completed or were terminated, 8 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 67 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Xueyan Zhao as lead sponsor.
Xueyan Zhao has 1 study filed under Thrombosis — fewer than ten, so there is no comparison to draw.
6 of the studies in Thrombosis with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05482269Shengjing HospitalAdverse Outcome of Acute Pulmonary Embolism by Artificial Intelligence System Based on CT Pulmonary Angiography | 2026-12-31 |
| NCT05098769Shengjing HospitalA Predictive Tool for Predicting Adverse Outcomes in Acute Pulmonary Embolism Patients Using CTPA. | 2026-12-31 |
| NCT06347276China National Center for Cardiovascular DiseasesCerebral Microembolization Associated With PFO Closure | 2026-12-31 |
| NCT04847752Tongji HospitalStudy of Predictive Factors Related to Prognosis of Patients With Ischemic Stroke Due to Large-artery Atherosclerosis | 2026-12-31 |
| NCT05300997The University of Hong KongTranslational Immunodiagnostics in Stroke (TrImS) | 2027-08-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 67 studies in Thrombosis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Patients with coronary heart disease who take dual antiplatelet therapy face two serious risks: thrombosis and major bleeding. This study aims to develop better ways to predict these risks and guide personalized treatment.
The investigators will use a large, long-term follow-up study of Chinese patients with coronary heart disease. This research plans to discover new biomarkers related to clot and bleeding risk. The study will combine information from proteins, metabolites, sugars attached to proteins, genes, and medical images. Using machine learning methods, the investigators will identify the most important markers and test them in the patient group of this study.
The investigators will then build new risk prediction models that include these new markers together with traditional risk scores (such as GRACE, PARIS, and Precise-DAPT). This study will check whether these new models are better than existing ones at predicting who will develop clots or bleeding and at helping doctors decide on the best treatment for each patient.
The new aspects of this research are: (1) using advanced multi-omics technology to find novel markers specifically for Chinese patients; (2) combining clinical, biological, and imaging data to improve prediction accuracy; and (3) using machine learning to create more precise risk models.
The goal is to provide doctors with a more accurate tool to assess each patient's risk of clots and bleeding. This will help them choose the safest and most effective antiplatelet treatment, reduce serious complications, and improve patient care.
The study population consists of patients with coronary heart disease who are receiving dual antiplatelet therapy after percutaneous coronary intervention. The study includes a retrospective cohort of approximately 10,154 patients with existing baseline and follow-up data and biospecimens, derived from a previously established patient cohort. In addition, a prospective cohort of at least 2,000 newly enrolled patients will be recruited.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For newly enrolled patients: voluntary written provided by the patient or legal representative, agreement to provide blood samples, and acceptance of follow-up procedures.
Exclusion Criteria:
For patients from the existing cohort:
For newly enrolled patients:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Approximately 10,154 patients with coronary heart disease selected from an established cohort of 18,701 patients based on inclusion/exclusion criteria.
At least 2,000 newly enrolled patients with coronary heart disease. Participants will be followed prospectively for thrombotic and bleeding events.
Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)
Composite of all-cause death, non-fatal myocardial infarction, ischemic stroke, and unplanned revascularization.
Time frame: Up to 24 months after enrollment
Major Bleeding Events
Bleeding Academic Research Consortium (BARC) type 3 or type 5 bleeding.
Time frame: Up to 24 months after enrollment
All-Cause Death
Time frame: Up to 24 months after enrollment
Myocardial Infarction
Time frame: Up to 24 months after enrollment
Stroke
Time frame: Up to 24 months after enrollment
Stent Thrombosis
Time frame: Up to 24 months after enrollment
Plan to share: Undecided
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Jan 2029, 41 months after the start.
Of 160 non-industry observational studies under Thrombosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 114. This study's planned 41 months is close to that.
Counting every sponsor, half of 189 studies reached it within 31 months; a quarter within 12 and three quarters within 99.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.